JPH0564930B2 - - Google Patents

Info

Publication number
JPH0564930B2
JPH0564930B2 JP61123220A JP12322086A JPH0564930B2 JP H0564930 B2 JPH0564930 B2 JP H0564930B2 JP 61123220 A JP61123220 A JP 61123220A JP 12322086 A JP12322086 A JP 12322086A JP H0564930 B2 JPH0564930 B2 JP H0564930B2
Authority
JP
Japan
Prior art keywords
alfuzosin
dysuria
bladder
patients
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61123220A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61277620A (ja
Inventor
Francois Regnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9319589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0564930(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of JPS61277620A publication Critical patent/JPS61277620A/ja
Publication of JPH0564930B2 publication Critical patent/JPH0564930B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP61123220A 1985-05-28 1986-05-27 排尿困難治療剤 Granted JPS61277620A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8507950A FR2582513B1 (fr) 1985-05-28 1985-05-28 Compositions pharmaceutiques contenant de l'alfuzosine
FR8507950 1985-05-28

Publications (2)

Publication Number Publication Date
JPS61277620A JPS61277620A (ja) 1986-12-08
JPH0564930B2 true JPH0564930B2 (2) 1993-09-16

Family

ID=9319589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61123220A Granted JPS61277620A (ja) 1985-05-28 1986-05-27 排尿困難治療剤

Country Status (12)

Country Link
US (1) US4661491A (2)
EP (1) EP0204597B1 (2)
JP (1) JPS61277620A (2)
AU (1) AU586684B2 (2)
CA (1) CA1261755A (2)
DE (1) DE3683318D1 (2)
DK (1) DK168029B1 (2)
FR (1) FR2582513B1 (2)
HU (1) HUT46221A (2)
IE (1) IE58595B1 (2)
IL (1) IL78934A (2)
ZA (1) ZA863957B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0663398A1 (en) * 1993-12-28 1995-07-19 Synthelabo Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
AU677968B2 (en) * 1992-09-25 1997-05-15 H. Lundbeck A/S DNA encoding human alpha 1 adrenergic receptors and uses thereof
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
WO1997017967A1 (en) * 1995-11-15 1997-05-22 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
NZ334018A (en) * 1996-08-29 1999-06-29 Synthelabo Multilayered controlled release tablet comprising a layer of alfuzosin hydrochloride and at least one layer of hydrophillic polymers
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
AU5234899A (en) 1998-07-30 2000-02-21 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO2000025782A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US20070105880A1 (en) * 2005-11-08 2007-05-10 Torrent Pharmaceuticals Limited Process for the preparation of alfuzosin
WO2007074364A1 (en) * 2005-12-26 2007-07-05 Aurobindo Pharma Limited Process for the preparation of alfuzosin
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
EP2042179A1 (en) * 2007-09-26 2009-04-01 sanofi-aventis Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
SMT202100546T1 (it) 2011-09-19 2021-11-12 Orexo Ab Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN113599385B (zh) * 2021-08-20 2023-01-03 兰州大学 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
FR2466462A2 (fr) * 1978-02-06 1981-04-10 Synthelabo Derives d'alkylenediamines, leur preparation et leur application en therapeutique
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0663398A1 (en) * 1993-12-28 1995-07-19 Synthelabo Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation

Also Published As

Publication number Publication date
DK246586A (da) 1986-11-29
DK246586D0 (da) 1986-05-27
EP0204597A2 (fr) 1986-12-10
DE3683318D1 (de) 1992-02-20
EP0204597A3 (en) 1989-08-16
FR2582513B1 (fr) 1988-08-05
JPS61277620A (ja) 1986-12-08
IL78934A0 (en) 1986-09-30
IL78934A (en) 1991-01-31
FR2582513A1 (fr) 1986-12-05
HUT46221A (en) 1988-10-28
DK168029B1 (da) 1994-01-24
CA1261755A (en) 1989-09-26
US4661491A (en) 1987-04-28
ZA863957B (en) 1987-01-28
AU586684B2 (en) 1989-07-20
AU5795186A (en) 1986-12-04
IE58595B1 (en) 1993-10-20
IE861395L (en) 1986-11-28
EP0204597B1 (fr) 1992-01-08

Similar Documents

Publication Publication Date Title
JPH0564930B2 (2)
CA2219502C (en) Methods and formulations for modulating the human sexual response
US20080145417A1 (en) Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
JP2005527599A (ja) 肥満および摂食障害におけるゾニサミドの使用
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
RU2308268C2 (ru) Производные арил- или гетероарилазолилкарбинолов для лечения недержания мочи
JP5049139B2 (ja) 内臓痛を治療するためのオキシコドンの使用
WO1998024411A2 (en) Method for oral administration of buspirone
US7767694B2 (en) Pharmaceutical composition having prokinetic effect
CA2471338C (en) Use of deoxypeganine for treating clinical depression
EP1469853A1 (en) Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d-pyrimidine for treating of urinary incontinence
US4687771A (en) Method for treatment of male impotence
TW201350118A (zh) 應力性尿失禁預防劑及／或治療劑
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
CN110279691B (zh) 一种外科术后护理镇痛药物及其用途
JP2013518915A (ja) ペントキシフィリンの便秘の予防または治療における応用
MXPA01012794A (es) Composicion farmaceutica para la terapia de sintomas del tracto urinario inferior.
JPH01316322A (ja) 尿管機能不全および良性前立腺肥大の治療薬
JP2772814B2 (ja) 記憶障害改善剤
JP2001233770A (ja) 勃起機能不全治療用の経口薬の組合わせ
JPWO2004022045A1 (ja) 下腹部及び／又は会陰部の疼痛改善剤
CN101171011A (zh) 用于治疗食欲紊乱的含有1-(3-氯苯基)-3-烷基哌嗪的药物组合物

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term